A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma Y. CaiFei WangZ. Sun PRECLINICAL STUDIES 27 October 2018 Pages: 799 - 809
The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer Huijun ZhaoJuan MaMan Zhang PRECLINICAL STUDIES 29 October 2018 Pages: 810 - 817
Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer Eriko YokoiSeiji MabuchiTadashi Kimura PRECLINICAL STUDIES 30 October 2018 Pages: 818 - 827
The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling Juan WangShumei MaQibing Mei PRECLINICAL STUDIES 19 November 2018 Pages: 828 - 836
Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells Elizabeth Hernandez MarinHana PaekXinyu Wang PRECLINICAL STUDIES 22 November 2018 Pages: 837 - 848
The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines Malgorzata KucinskaHelena MieszczakThomas Erker PRECLINICAL STUDIES Open access 29 November 2018 Pages: 849 - 864
A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells Wanbin YangXiuli GongChao Huang PRECLINICAL STUDIES 29 November 2018 Pages: 865 - 875
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer Weihua HouQingyun YuanMin Yu PRECLINICAL STUDIES 04 December 2018 Pages: 876 - 889
The availability of drug by liposomal drug delivery Evelien A. W. SmitsJosé A. SoetekouwHerman Vromans PRECLINICAL STUDIES Open access 13 December 2018 Pages: 890 - 901
Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells Blair P. CurlessNne E. UkoDiane F. Matesic PRECLINICAL STUDIES 13 December 2018 Pages: 902 - 911
MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells Mariana Franzoni MaioralNatália Marceli StefanesMaria Cláudia Santos-Silva PRECLINICAL STUDIES 19 December 2018 Pages: 912 - 922
MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer Shaohua GeHaiyang ZhangYi Ba PRECLINICAL STUDIES 04 January 2019 Pages: 923 - 934
Screening, identification of prostate cancer urinary biomarkers and verification of important spots Huijun ZhaoXuhong ZhaoMan Zhang PRECLINICAL STUDIES 04 January 2019 Pages: 935 - 947
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib Titto AugustineRadhashree MaitraSanjay Goel PRECLINICAL STUDIES 05 January 2019 Pages: 948 - 960
Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice Ya-Jen ChangChung-Li HoChih-Hsien Chang PRECLINICAL STUDIES 05 January 2019 Pages: 961 - 972
The rhenium(I)-diselenoether anticancer drug targets ROS, TGF-β1, VEGF-A, and IGF-1 in an in vitro experimental model of triple-negative breast cancers Philippe ColleryVijay VeenaDidier Desmaele PRECLINICAL STUDIES 11 January 2019 Pages: 973 - 983
The cellular effects of novel triazine nitrogen mustards in glioblastoma LBC3, LN-18 and LN-229 cell lines Rafał KrętowskiDanuta DrozdowskaMarzanna Cechowska-Pasko PRECLINICAL STUDIES Open access 15 January 2019 Pages: 984 - 993
In vitro and in vivo cytotoxic activity and human serum albumin interaction for a methoxy-styryl-thiosemicarbazone Otávio Augusto ChavesIsabela S. de CastroAurea Echevarria PRECLINICAL STUDIES 19 January 2019 Pages: 994 - 1005
Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma Yi LuoAnqi ZengYongmei Xie PRECLINICAL STUDIES 25 January 2019 Pages: 1006 - 1013
Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo Svetlana PaskasEmanuela MazzonDanijela Maksimovic-Ivanic PRECLINICAL STUDIES 01 February 2019 Pages: 1014 - 1028
Modified ingenol semi-synthetic derivatives from Euphorbia tirucalli induce cytotoxicity on a large panel of human cancer cell lines Viviane A. O SilvaMarcela N. RosaRui M. Reis PRECLINICAL STUDIES 01 February 2019 Pages: 1029 - 1035
Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo Juan MaTengfei ShangMan Zhang PRECLINICAL STUDIES 01 February 2019 Pages: 1036 - 1043
The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model Narine GhazaryanNaira MovsisyanElsa Logarinho PHASE I STUDIES 25 January 2019 Pages: 1044 - 1051
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer Deaglan McHughMario EisenbergerMichael J. Morris PHASE I STUDIES 06 February 2019 Pages: 1052 - 1060
A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors Toshihiko DoiTakeshi AramakiRyo Nakajima PHASE I STUDIES Open access 09 January 2019 Pages: 1061 - 1074
Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters Paul BerveillerOlivier MirSophie Gil PRECLINICAL STUDIES 26 October 2018 Pages: 1075 - 1085
The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States Hiroki NakayamaNaoki MatsumaruKatsura Tsukamoto Phase III Studies 31 May 2018 Pages: 1086 - 1093
Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in Taiwan I-Chen Sun PHASE III STUDIES 05 January 2019 Pages: 1094 - 1106
Human antigen R and drug resistance in tumors Fenghai ZhouFa ZhangXupan Wei REVIEW 05 January 2019 Pages: 1107 - 1116